A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL). This is an ASCO Meeting Abstract from the ...
MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...
Please provide your email address to receive an email when new articles are posted on . Multiple studies published since this summer suggest chimeric antigen receptor T-cell therapies are comparably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results